JPRN-UMIN000012778招募中2 期
OCV-C01 as a combination therapy of peptide-based cancer vaccines for patients with advanced biliary tract cancer refractory to priortherapy : Phase II study - OCV-C01 therapy for patients with advanced biliary tract cancer
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) The patient have history of cancer immunotherapy. 2) Double cancer for less than one year, except cancer in situ or intramucosal cancer. 3) The primary disease has permeated and bleeding is strongly suspected. 4) Interstitial pneumonia or pulmonary fibrosis or past history. 5) Ascites fluid or pleural effusion with difficult control. 6) Pericardial effusion in need of puncture and discharge. 7) Serious infection or being suspected. 8) Brain metastasis or being suspected by clinical symptoms. 9) Serious mental disorder or serious neuropathy. 10) Cardiac disease, lung disease, renal disease, or liver disease that is difficult to control. 11) Grade 4 (CTCAE v4.0) or co-existing disease with poor control. 12) History of myocardial infarction, severe unstable angina pectoris, CABG, congestive heart failure, cerebrovascular accident, pulmonary embolism, deep-vein thrombosis, or other severe thromboembolism within 12 months before administration of OCV-C01. 13) Unhealed traumatic lesion, including traumatic fracture. 14) Evidence of bleeding diathesis or severe coagulopathy, or past histories. 15) Need continuous medication of antiplatelet drug except aspirin. 16) High blood pressure with poor control in spite of getting suitable medical treatment. 17) Heart failure that requires medical treatment. 18) Patients who require systemic administration of the following agents during the study treatment period. (1) Corticosteroid (2) Immunosuppresant, Immunostimulant (3) G-CSF, M-CSF (4) Erythropoietin 20) The result of HLA-A*24:02 has become clear beforehand. 21) Pregnant females, or nursing mothers who cannot stop lactation. Patient or patients partner unwilling to use adequate contraception during the study period and until 180 days after the last administration day for male, or until 120 days after the last administration day for female. 22) As determined by the principal investigator or the sub-investigator the subject are not adequate to participate in the trial.
研究者
相似试验
招募中
1 期
Phase I/II clinical trial of novel peptide-based cancer vaccine IMA901 for patients with advanced renal cell carcinomaRenal cell carcinomaJPRN-UMIN000006938Departments of Urology and Translational Cancer Drug Development, Kyoto Prefectural University of Medicine15
进行中（未招募）
不适用
Peptide-based vaccine in combination or not with chemotherapy in melanoma patients: a phase II randomized clinical study. - NDMedDRA version: 12.0Level: HLTClassification code 10027156Term: Skin melanomas (excl ocular)advanced melanomaEUCTR2008-008211-26-ITISTITUTO SUPERIORE DI SANITA`
已完成
不适用
OTSGC-A24 therapeutic peptide Vaccine + Nivolumab – a combination immunotherapy Phase Ib study for inoperable or metastatic gastric cancer.NeoplasmsKCT0005481Yonsei University Health System, Severance Hospital7
已完成
1 期
Cancer peptide vaccine therapy for patients with advanced metastatic colorectal cancer. Phase I/II clinical trial.Colorectal cancerJPRN-UMIN000004945Tokai University School of Medicine20
已完成
1 期
Phase I/II clinical trial of WT1 peptide-based vaccine for the patients with malignant tumors.Malignant solid tumors, Malignant lymphoma, Multiple Myeloma, Acute leukemiaJPRN-UMIN000002001Department of Cancer immunotherapy, Osaka University Graduate School of Medicine30